{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-013888","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.237678+00:00","generated_at":"2026-06-04T04:25:20.593727+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aquestive appoints Abigail L. Jenkins to Board of Directors","bullets":["Ms. Jenkins appointed as Class II director effective April 1, 2024, term through 2026 annual meeting.","Appointed to Nominating and Corporate Governance Committee; board size increased from 7 to 8 members.","Ms. Jenkins will receive 57,000 stock options under 2018 Equity Incentive Plan, vesting in 1/3 annual increments.","Board determined Ms. Jenkins is an independent director under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-013888","json":"https://secwatch.observer/filing/0001628280-24-013888.json","markdown":"https://secwatch.observer/filing/0001628280-24-013888.md","text":"https://secwatch.observer/filing/0001628280-24-013888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024013888/0001628280-24-013888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024013888/aqst-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:25:20.593727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"648ffc80e2","claim":"Abigail L. Jenkins was appointed as Director at Aquestive Therapeutics, Inc..","evidence_excerpt":"On April 1,2024, Aquestive Therapeutics, Inc. (the “Company”) announced the appointment of Abigail L. Jenkins to the Board of Directors of the Company (the “Board”), effective April 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024013888/0001628280-24-013888-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}